MARKET ACCESS 101 SPONSOR REGISTRATION

8:30 am
NETWORKING BREAKFAST

9:00am
Welcome & Housekeeping 
Emcee Andrew Retfalvi, Vice President, Health & Life Sciences, Global Public Affairs

9:15am
Overview of Market Access and Canadian Landscape
Arvind Mani, Managing Director and Co-founder, MORSE Consulting

Market Access in Canada is a broad field encompassing many different areas. Join Arvind Mani as he introduces the field (e.g., what market access entails in the Canadian market) and provides an overview of what market access professionals need to know in light of the changing public policy landscape affecting the profession.

10:00am
Evidence - Clinical and Real World
Lindy Forte, Division Head - Market Access and Pricing,  EVERSANA

This session will focus on the data expectations of payers and HTA bodies as they evaluate and consider the value of new drug products for drug plan listing. We will also review the evolving role of real-world evidence (RWE) in reimbursement.

10:45am 
NETWORKING BREAK

11:00am 
Pricing in Canada - PMPRB & MFN
Anna Apostolakis. Associate Principal, Price Regulation Consulting, IQVIA

The new PMPRB Guidelines have established a revised framework for the review of prices for all patented medicines. Separately, emerging MFN dynamics—outside the PMPRB process—are introducing broader uncertainty for pharmaceutical pricing strategy, making price setting increasingly complex. This presentation focuses on what is now defined under PMPRB and key considerations for manufacturers of patented drugs.

11:30am
AGM, LUNCH & SPEED NETWORKING

1:00pm
Introduction to the Private Payer Market
Shanta Zurock, Senior Director, Reimbursement Strategy, Innomar Cencora

Join Shanta as she walks through a brief overview of private drug coverage in Canada: from where drugs fit overall into employer-sponsored benefits, to a discussion on the different types of management strategies insurers use to control drug costs.

1:30pm
PSP Overview
Alison Oliver, Senior Director, Customer Experience, Cencora Innomar Strategies

This session will cover the basics of a Patient Support Program (PSP), including why PSPs are needed in Canada, what are the key elements of a PSP, what is a typical PSP journey as well as drug lifecycle considerations, how PSPs are leveraging data for Real World Evidence (RWE), preparing for an RFP and metrics to measure success when designing a PSP.

2:00pm
Preparing a HTA Submission Dossier for Public Payers
Patrick Mott, Associate Director Market Access Pricing, EVERSANA

This session will serve as an introduction to planning and developing the components of an HTA submission dossier. Due to time constraints, the focus of this session will be on CDA-AMC.

2:45pm
NETWORKING BREAK

3:00pm
Health Economics and Outcomes Research (HEOR)
Jean-Éric Tarride, McMaster Chair in Health Technology Management, Professor, Department of Health Research Methods, Evidence, And Impact (HEI), Faculty of Health Sciences, McMaster University

This session will provide an overview of key HEOR concepts to support HTA submissions, including the types of economic evaluations, model-based economic evaluations and budget impact analyses.

3:45pm
The pan-Canadian Pharmaceutical Alliance (pCPA)
Sang Mi Lee, Chief Strategy Officer, MORSE Consulting

This session will provide an overview of the pCPA (e.g., history, processes, outcomes, and future outlook) before simulating a mock negotiation.

4:45pm Closing Remarks
Emcee Andrew Retfalvi, Vice President, Health & Life Sciences, Global Public Affairs